Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: Inhibition by doxycycline and by monoclonal antibody VP-1

Blood

Volumn 89, Issue 6, 1997, Pages 1954-1962

  Tsai, Han Mou ^a   Sussman, Ira I ^b   Ginsburg, David ^b   Lankhof, Hanneke ^b   Sixma, Jan J ^b   Nagel, Ronald L ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CATION; DOXYCYCLINE; GUANIDINE; METALLOPROTEINASE; MONOCLONAL ANTIBODY; MUTANT PROTEIN; RECOMBINANT PROTEIN; VON WILLEBRAND FACTOR;

ANIMAL CELL; ARTICLE; ENZYME ACTIVITY; METAL BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; VON WILLEBRAND DISEASE;

EID: 0030980679     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.6.1954     Document Type: Article

References (27)

1. Tsai HM, Nagel RL, Hatcher VB, Sussman II: Multimeric composition of endothelial cell-derived von Willebrand factor. Blood 73:2074, 1989
2. Kaul DK, Nagel RL, Chen D, Tsai HM: Sickle erythrocyteendothelial interaction in microcirculation: The role of von Willebrand factor and implications for vasoocclusion. Blood 81:2429, 1993
3. Hattori R, Hamilton KK, McEver RP, Sims PJ: Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 264:9053, 1989
4. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM: Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 87:6306, 1990
5. Tsai HM, Sussman II, Nagel RL: Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 83:2171, 1994
6. Tsai HM: Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium. Blood 87:4235, 1996
7. Dent JA, Galbusera M, Ruggeri ZM: Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 88:774, 1991
8. Tsai HM, Nagel RL, Sussman II: Subunit composition of plasma von Willebrand factor multimers: Evidence for a non-proteolytic mechanism resulting in apparent increase in proteolytic fragments. Thromb Res 63:179, 1991
9. Furlan M, Robles R, Affolter D, Meyer D, Baillod P, Lämmle B: Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci USA 90:7503, 1993
10. Furlan M, Robles R, Lämmle B: Purification and characterization of a protease from human plasma, cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Thromb Haemost 93:1158a, 1995 (abstr)
11. Woessner JF Jr: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145, 1991
12. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM: Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54:4726, 1994
13. Ginsburg D, Bowie EJW: Molecular genetics of von Willebrand disease. Blood 79:2507, 1992
14. Gralnick HR, Williams SB, McKeown LP, Maisonneuve P, Jenneau C, Sultan Y, Rick ME: In vitro correction of the abnormal multimeric structure of vWF in type IIA vWD. Proc Natl Acad Sci USA 82:5968, 1985
15. Batlle J, Lopez-Fernandez MF, Campos M, Justica B, Berges C, Navarro JL, Diaz-Cremades JM, Kasper CK, Dent JA, Ruggeri ZM, Zimmerman TS: The heterogeneity of type IIA von Willebrand's disease: Studies with protease inhibitors. Blood 68:1207, 1986
16. Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD: Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 71:1366, 1988
17. Lankhof H: Structure and function of human von Willebrand factor. PhD thesis. University Utrecht, Utrecht, The Netherlands, 1996
18. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM: Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 87:6306, 1990
19. Berkowitz SD, Federici AB: Sialic acid prevents loss of large von Willebrand factor multimers by protecting against amino-terminal proteolytic cleavage. Blood 72:1790, 1988
20. Lyons SE, Brack ME, Bowie EJW, Ginsburg D: Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 267:4424, 1992
21. Albert A, Rees CW: Avidity of the tetracyclines for the cations of metals. Nature 177:433, 1956
22. Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH: Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (type IIC, IID, and IIE). J Clin Invest 77:947, 1986
23. Johansson S, Smedsrod B: Identification of a plasma gelatinase in preparations of fibronectin. J Biol Chem 261:4363, 1986
24. Vartio T, Baumann M: Human gelatinase/type IV procollagenase is a regular plasma component. FEBS Lett 255:285, 1989
25. Rajabi M, Dean DD, Woessner JF Jr: High levels of serum collagenase in premature labor - A potential biochemical marker. Obstetr Gynecol 69:179, 1987
26. Zucker S, Lysik RM, Zarrabi HM, Moll U, Tickle SP, Stetler-Stevenson W, Baker TS, Docherty AJP: Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complex in cancer. Potential use in predicting metastasis and monitoring treatment. Ann NY Acad Sci 732:248, 1994
27. Sorsa T, Ding Y, Salo T, Lauhio A, Teronen O, Ingman T, Ohtani H, Andoh N, Takeha S, Konttinen YT: Effects of tetracyclines on neutrophil, gingival, and salivary collagenases. A functional and Western-blot assessment with special reference to their cellular sources in periodontal diseases. Ann NY Acad Sci 732:112, 1994